Inactive Instrument

Ignyta Inc Stock

Equities

US4517311035

Biotechnology & Medical Research

on all our subscriptions*

Exceptional extension!

Take advantage of the offer

* See conditions on site

Chart Ignyta Inc

Duration

Period

Style

Latest news about Ignyta Inc

Bayer : Roche takes on Loxo, Bayer in gene-defined cancer class	18-10-21	RE
Roche : to buy U.S. cancer drugmaker Ignyta for $1.7 billion	17-12-22	RE

Press releases Ignyta Inc

Ignyta : Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor	17-12-29	BU
Ignyta : Roche and Ignyta Reach Definitive Merger Agreement	17-12-22	BU
Ignyta : to Participate at the Global Mizuho Investor Conference	17-11-29	BU
Ignyta : to Present at the 29th Annual Piper Jaffray Healthcare Conference	17-11-22	BU
Ignyta : Reports Granting of Inducement Awards	17-11-16	BU

More press releases

News in other languages on Ignyta Inc

Apple : Les valeurs à suivre à Wall Street	17-12-26
Agile Therapeutics : Wall Street marque le pas avant Noël, Nike pèse	17-12-22
Citigroup : Roche rachète le laboratoire américain Ignyta 1,7 milliard de dollars	17-12-22

Managers and Directors - Ignyta Inc

Managers	Title	Age	Since
Sean Johnston CEO	Chief Executive Officer	-	18-02-07
Edward Harrington PRN	Corporate Officer/Principal	-	18-02-06
Bernard Parker SAM	Sales & Marketing	-	15-07-21

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.62%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW